Back

A genome-wide in vivo CRISPR screen identifies neuroprotective strategies in the mouse and human retina

Shen, N.; Fitzpatrick, M. J.; Harding, E. G.; Rebba, S.; Ruzycki, P. A.; Kerschensteiner, D.

2025-03-24 neuroscience
10.1101/2025.03.22.644712 bioRxiv
Show abstract

Retinitis pigmentosa (RP) is a genetically diverse blinding disorder lacking broadly effective therapies. We performed a genome-wide in vivo CRISPR knockout screen in mice carrying the P23H rhodopsin mutation (the most common cause of autosomal dominant RP in the United States) to systematically identify neuroprotective genes. We discovered multiple knockouts that accelerated rod photoreceptor loss, validated top candidates, and showed that overexpressing two genes--UFD1 and UXT--preserved rods and cones, maintained retinal function, and improved visual behaviors. To accelerate translation, we developed a human P23H RP model in adult retinal explants, recreating key disease features. UFD1 and UXT augmentation prevented photoreceptor loss in human P23H retinas. Our findings establish a pipeline for systematic identification and translational testing of neuroprotective genes in mouse and human RP models, provide a novel set of validated candidate genes, and underscore the therapeutic promise of UFD1 and UXT as mutation-agnostic strategies to preserve vision.

Published in Neuron (predicted rank #6) · training set

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.